Cosette Pharmaceuticals acquires U.S. commercial rights to SYMPAZAN and additional branded products from Assertio, expanding its neurology and pain portfolio with approximately $49 million in annual net sales.
Written by: A. Mohamed Musharaf, BPharm
Reviewed By: Pharmacally Editorial Team
Cosette Pharmaceuticals has announced the acquisition of U.S. commercial rights to a portfolio of branded products from Assertio Holdings, significantly expanding its branded business and strengthening its commercial footprint. The transaction includes SYMPAZAN along with several established therapies in pain, inflammation, and autoimmune disease, collectively generating approximately $49 million in annual net product sales.
SYMPAZAN is an FDA-approved therapy indicated as adjunctive treatment for seizures associated with Lennox–Gastaut syndrome in patients two years of age and older. As the first and only oral film formulation of clobazam, the product offers an alternative route of administration, particularly useful for patients with swallowing difficulties.
The product is supported by long-term patent protection extending into the 2040 timeframe, positioning it as a durable growth asset within Cosette’s branded portfolio and providing the company with entry into neurology and rare disease markets.
In addition to SYMPAZAN, the acquisition includes several established branded products used in pain and inflammatory conditions, including INDOCIN (indomethacin), SPRIX, ZIPSOR, CAMBIA, and OTREXUP. These products are used across indications including acute pain, migraine, inflammatory disorders, and autoimmune conditions, broadening Cosette’s therapeutic reach and adding immediate commercial revenue.
The acquisition aligns with Cosette’s strategy of expanding through commercially available branded medicines with established market demand. By adding SYMPAZAN and the pain portfolio, the company strengthens its position in specialty pharmaceuticals while diversifying into neurology, rare disease, and rheumatology-related markets.
The agreement includes a transition period during which manufacturing, supply chain operations, pharmacovigilance, and regulatory responsibilities will be transferred from Assertio to Cosette. This phased integration is intended to ensure continuity of supply and maintain uninterrupted access for patients and healthcare providers.
Reference
Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from Assertio, 08 April 2026, https://cosettepharma.com/cosette-pharmaceuticals-expands-branded-portfolio-through-acquisition-of-sympazan-and-additional-products-from-assertio/
About the Writer
Sana Jamil Khan is a B.Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.
